Adage Capital Partners Gp, L.L.C. Alkermes Plc. Transaction History

Adage Capital Partners Gp, L.L.C.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$22.0 - $31.87 $22.2 Million - $32.2 Million	-1,010,000 Reduced 92.66%	80,000 $1.79 Million
Q2 2022 Aug 15, 2022	BUY	$26.4 - $30.54 $28.8 Million - $33.3 Million	1,090,000 New	1,090,000 $32.5 Million
Q3 2018 Nov 14, 2018	SELL	$38.6 - $46.12 $6.76 Million - $8.07 Million	-175,000 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$40.56 - $51.36 $7.1 Million - $8.99 Million	175,000 New	175,000 $7.2 Million
Q1 2018 May 15, 2018	SELL	$53.61 - $67.26 $21.4 Million - $26.9 Million	-400,000 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$47.69 - $55.39 $13.1 Million - $15.2 Million	275,000 Added 220.0%	400,000 $21.9 Million
Q3 2017 Nov 14, 2017	BUY	$49.16 - $54.45 $6.15 Million - $6.81 Million	125,000	125,000 $6.36 Million

362

181M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $4.9B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.